Wei Zhong
Chief Executive Officer Wayshine Biopharm
Seminars
            Wednesday 28th January 2026
        
        Validating DNA-PK Inhibition as a Radiosensitizer to Overcome Past Challenges & Advance into the Clinic
    
    
        
            1:45 pm
            
        
    
    • Reviewing lessons learned from past DNA-PK inhibitor programs and how improved potency, PK, and selectivity address prior limitations
• See how Wayshine Pharma is advancing WN-C001 to enhance radiotherapy efficacy with a favorable safety profile
• Highlighting translational insights and the development path toward clinical validation of DNA-PK inhibition as a radio-sensitization strategy
 
					